|
Volumn 96, Issue 10, 2000, Pages 3544-3552
|
Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma
a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
CD19 ANTIGEN;
CD64 ANTIGEN;
GRANULOCYTE COLONY STIMULATING FACTOR;
IMMUNOGLOBULIN F(AB')2 FRAGMENT;
IMMUNOGLOBULIN FC FRAGMENT;
LYMPHOCYTE ANTIGEN RECEPTOR;
MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;
MONOCLONAL ANTIBODY;
BISPECIFIC ANTIBODY;
FC RECEPTOR;
IMMUNOGLOBULIN G;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANTIBODY SPECIFICITY;
ARTICLE;
B CELL LYMPHOMA;
CELL ACTIVATION;
CONTROLLED STUDY;
CYTOTOXICITY;
IMMUNITY;
LYMPHOMA CELL;
MOUSE;
NONHUMAN;
POLYMORPHONUCLEAR CELL;
PRIORITY JOURNAL;
T LYMPHOCYTE;
TRANSGENIC MOUSE;
ANIMAL;
BAGG ALBINO MOUSE;
BIOSYNTHESIS;
CALCIUM SIGNALING;
CANCER TRANSPLANTATION;
CELL SURVIVAL;
COMPARATIVE STUDY;
DRUG EFFECT;
HUMAN;
IMMUNOLOGY;
IMMUNOTHERAPY;
LEUKOCYTE ACTIVATION;
METABOLISM;
PATHOLOGY;
STANDARD;
ANIMALS;
ANTIBODIES, BISPECIFIC;
CALCIUM SIGNALING;
CELL SURVIVAL;
CYTOTOXICITY, IMMUNOLOGIC;
GRANULOCYTE COLONY-STIMULATING FACTOR;
HUMANS;
IMMUNOGLOBULIN G;
IMMUNOTHERAPY;
LYMPHOMA, B-CELL;
MICE;
MICE, INBRED BALB C;
MICE, TRANSGENIC;
NEOPLASM TRANSPLANTATION;
NEUTROPHIL ACTIVATION;
RECEPTORS, IGG;
T-LYMPHOCYTES;
|
EID: 0034668385
PISSN: 00064971
EISSN: None
Source Type: Journal
DOI: 10.1182/blood.v96.10.3544.h8003544_3544_3552 Document Type: Article |
Times cited : (62)
|
References (47)
|